# 22.11 Platform release now live!

**URL:** <https://community.opentargets.org/t/22-11-platform-release-now-live/870>\
**Category:** Releases\
**Tags:** ot-platform\
**Created:** [24 November 2022 15:27 UTC](https://community.opentargets.org/t/22-11-platform-release-now-live/870 "2022-11-24T15:27:17Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![hcornu](https://dub1.discourse-cdn.com/flex017/user_avatar/community.opentargets.org/hcornu/32/716_2.png) [@hcornu](https://community.opentargets.org/u/hcornu)\
**Post date:** [24 November 2022 15:27 UTC](https://community.opentargets.org/t/22-11-platform-release-now-live/870/1 "2022-11-24T15:27:17Z")

</div>

We have just released the latest update to the Open Targets Platform — 22.11.

This release integrates new gene burden data for Parkinson’s disease, features updated classifications for clinical trial stop reasons, and displays variant functional consequences for Gene2Phenotype and Orphanet.

## Key highlights for this release:

This release integrates 14,611,717 evidence strings to build 6,960,486 target-disease associations between 22,274 diseases and 62,678 targets from the following 22 public resources:

- 1,803,263 genetic evidence from [European Variation Archive (EVA)](http://www.ebi.ac.uk/eva/)
- 782,147 genetic evidence from [Open Targets Genetics](https://genetics.opentargets.org/)
- 3,007 genetic evidence from [Gene2Phenotype](https://www.ebi.ac.uk/gene2phenotype)
- 31,946 genetic evidence from the[Genomics England PanelApp](https://bioinfo.extge.co.uk/crowdsourcing/PanelApp/)
- 1,866 genetic evidence from [ClinGen](https://search.clinicalgenome.org/kb/gene-validity/)
- 6,156 genetic evidence from Orphanet
- 27,271 genetic evidence from Gene burden
- 4,143 genetic evidence from [UniProt Literature](https://www.uniprot.org/)
- 14,669 somatic evidence from [European Variation Archive (EVA)](http://www.ebi.ac.uk/eva/)
- 3,299 somatic evidence from[intOGen](https://www.intogen.org/)
- 67,339 somatic evidence from the[Cancer Gene Census](http://cancer.sanger.ac.uk/census/)
- 26,228 somatic evidence from [Uniprot](http://www.uniprot.org/)
- 600,783 drug evidence from [ChEMBL](https://www.ebi.ac.uk/chembl/)
- 230,903 expression evidence from [Expression Atlas](https://www.ebi.ac.uk/gxa/home)
- 10,413 affected pathway evidence from [Reactome](https://reactome.org/)
- 72,294 affected pathway evidence from [SLAPenrich](https://saezlab.github.io/SLAPenrich/)
- 378 affected pathway evidence from [PROGENy](https://saezlab.github.io/progeny/)
- 390 systems biology evidence from [SysBio](https://saezlab.github.io/progeny/)
- 1,298 somatic evidence from the [Cancer Genome Interpreter](https://www.cancergenomeinterpreter.org/home)
- 1,838 CRISPR-Cas9 (Cancer Cell Lines) evidence from[Behan et al. 2019](https://europepmc.org/abstract/MED/30971826)
- 1,053,140 mouse model evidence from [IMPC](https://www.mousephenotype.org/)
- 9,868,946 scientific literature evidence from co-occurence mining in [Europe PMC](https://europepmc.org/)

Additionally, the Platform now allows users to explore data on 12,854 drugs.

For more details, read the [22.11 blog post](https://blog.opentargets.org/open-targets-platform-22-11-release/).